

Sharmila Banerjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312310/publications.pdf>

Version: 2024-02-01

155
papers

2,727
citations

218677

26
h-index

254184

43
g-index

155
all docs

155
docs citations

155
times ranked

2305
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimation of Absorbed Doses of Indigenously Produced ^{177}Lu -DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added ^{177}Lu -DOTA-TATE and the Trend with Multiple Cycles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 314-325.	1.0	1
2	Automated Radiochemical Synthesis of Pharmaceutical Grade [^{18}F]FLT using ^{18}F -O-(benzoyl)-2,3-dihydrothymidine precursor and its Sep-Pak [®] Purification employing Selective Elution from Reversed Phase. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2022, 37, 314-325.	1.0	1
3	Clinical Dose Preparation of ^{177}Lu -DOTA-Pertuzumab Using Medium Specific Activity $^{177}\text{LuCl}_3$ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 384-402.	1.0	2
4	Examining Absorbed Doses of Indigenously Developed ^{177}Lu -PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 292-304.	1.0	12
5	Initial clinical evaluation of indigenous ^{90}Y -DOTATATE in sequential duo-PRRT approach (^{177}Lu -DOTATATE and ^{90}Y -DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, ^{90}Y -DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 73-81.	0.5	5
6	Clinical efficacy of Sep-Pak [®] assisted one pot automated synthesis of pharmaceutical grade [^{18}F]FLT using ^{18}F -O-(benzoyl)-2,3-dihydrothymidine precursor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 327, 585-596.	1.5	0
7	On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of ^{90}Y -DOTATATE Patient Dose. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 143-159.	1.0	2
8	On the production of pharmaceutical grade indium-111-chloride in the medical cyclotron from natural cadmium target and its use in formulation of diagnostic patient dose of ^{111}In -pentetate for imaging somatostatin receptor overexpression. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 328, 835-846.	1.5	0
9	Production, characterization and in-vitro applications of single-domain antibody against thyroglobulin selected from novel T7 phage display library. <i>Journal of Immunological Methods</i> , 2021, 492, 112990.	1.4	5
10	Prospective evaluation of organ-specific dose and lesional doses following therapeutic [^{177}Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity. <i>Nuclear Medicine Communications</i> , 2021, 42, 1076-1084.	1.1	0
11	Therapeutic Multidose Preparation of a Ready-to-Use ^{177}Lu -PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 682-692.	1.0	2
12	Quercetin induces proteolysis of mesenchymal marker vimentin through activation of caspase-3, and decreases cancer stem cell population in human papillary thyroid cancer cell line.. <i>Phytomedicine Plus</i> , 2021, 1, 100108.	2.0	3
13	Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. <i>Journal of Liposome Research</i> , 2020, 30, 274-284.	3.3	12
14	Availability of both [^{177}Lu]Lu-DOTA-TATE and [^{90}Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 756-758.	6.4	12
15	Clinical utility of ^{177}Lu -DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. <i>Head and Neck</i> , 2020, 42, 401-416.	2.0	50
16	Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 disease course?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1793-1797.	6.4	9
17	Sequential Duo- ¹⁸ F-Fluoride Peptide Receptor Radionuclide Therapy With Indigenous ^{90}Y -DOTATATE and ^{177}Lu -DOTATATE in Large-Volume Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2020, 45, 714-715.	1.3	3
18	Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: Development, characterization, in-vitro studies. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 2018-2027.	7.5	34

#	ARTICLE	IF	CITATIONS
19	Technetium labeled doxorubicin loaded silk fibroin nanoparticles: Optimization, characterization and in vitro evaluation. Journal of Drug Delivery Science and Technology, 2020, 56, 101539.	3.0	5
20	Novel radioassay for anti-thyropoxidase autoantibodies using protein A coupled magnetizable cellulose particles as an immunoabsorbent. Journal of Radioanalytical and Nuclear Chemistry, 2020, 323, 1041-1046.	1.5	2
21	One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 178-211.	1.0	3
22	Clinical Efficacy of Sodium [99mTc] Pertechnetate from Low Specific Activity 99Mo/99mTc Autosolex Generator in Hospital Radiopharmacy Centre. Nuclear Medicine Review, 2020, 23, 1-14.	0.5	2
23	Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷ Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-À-vis Gleason score in such cohort. British Journal of Radiology, 2019, 92, 20190380.	2.2	44
24	Microarray immunoassay for thyrotropin on track-etched membranes using radiotracers. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 99-104.	1.5	1
25	Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. Clinical Nuclear Medicine, 2019, 44, e318-e322.	1.3	40
26	Potential immunomodulatory effect of allelochemical juglone in mice vaccinated with BCG. Toxicon, 2019, 157, 43-52.	1.6	6
27	Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. Journal of Nuclear Medicine Technology, 2019, 47, 292-299.	0.8	0
28	A compact solvent extraction based 99Mo/99 mTc generator for hospital radiopharmacy. Applied Radiation and Isotopes, 2019, 143, 41-46.	1.5	5
29	Purification of 99Mo and 99mTc from radioactive traces of Nb, Zr, and Y impurities: method applicable in the purification of the spent 100/99Moâ€“99mTc generator. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 809-815.	1.5	1
30	Production, separation and supply prospects of ⁶⁷ Cu with the development of fast neutron sources and photonuclear technology. Radiochimica Acta, 2018, 106, 549-557.	1.2	12
31	Preparation and comparative evaluation of ^{99m} Tcâ€“HYNICâ€“NGR and ^{99m} Tcâ€“HYNICâ€“PEG ₂ â€“NGR as tumorâ€“targeting molecular imaging probes. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 68-76.	1.0	4
32	The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results. Nuclear Medicine Communications, 2018, 39, 1061-1063.	1.1	4
33	¹⁷⁷ Luâ€“DOTMP induces G2/M cell cycle arrest and apoptosis in MG63 cell line. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 837-846.	1.0	8
34	Jugloneâ€“ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22176.	3.0	9
35	Preparation and preliminary evaluation of a tris-metronidazole-99mTc(CO) ₃ complex for targeting tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1203-1210.	1.5	6
36	Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World Journal of Nuclear Medicine, 2018, 17, 228-235.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Radiosynthesis and evaluation of a ^{99m} Tc-folic acid radiotracer prepared using [^{99m} TcN(PNP)] ²⁺ metal fragment. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1329-1332.	2.2	2
38	Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of ¹⁷⁰ Tm-EDTMP prepared using in-house freeze-dried EDTMP kit. <i>Applied Radiation and Isotopes</i> , 2017, 122, 7-13.	1.5	4
39	Preparation of clinical-scale ¹⁷⁷ Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 234-241.	1.0	10
40	⁴⁺ ™ Mixed Ligand Strategy for the Preparation of ^{99m} Tc-Radiopharmaceuticals for Hypoxia Detecting Applications. <i>ChemistrySelect</i> , 2017, 2, 2910-2916.	1.5	16
41	In Vitro Evaluation of ¹⁸⁸ Re-HEDP: A Mechanistic View of Bone Pain Palliations. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 184-191.	1.0	5
42	Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 1-10.	3.3	23
43	Synthesis of O-(²⁻ [¹⁸ F]fluoropropan- ²⁻ yl)-l-tyrosine (1-[¹⁸ F]FPT) via Ni(II) complex of (S) tyrosine schiff™s base precursor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 314, 483-490.	1.5	0
44	A zwitterionic pH responsive ES IPT-Based fluorescence Turn-On™Al ³⁺ ion sensing probe and its bioimaging applications. <i>Sensors and Actuators B: Chemical</i> , 2017, 253, 1012-1025.	7.8	22
45	Developing a dedicated comprehensive ± radionuclide therapy program. <i>Nuclear Medicine Communications</i> , 2017, 38, 103-105.	1.1	2
46	¹⁷⁰ Tm-EDTMP. <i>Clinical Nuclear Medicine</i> , 2017, 42, 235-236.	1.3	2
47	Preparation and preliminary bioevaluation of ⁶⁸ Ga-oxine in lipiodol as a potential liver imaging agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 311, 263-268.	1.5	5
48	Synthesis and comparative <i>in vivo</i> evaluation of ^{99m} Tc(^{CO}) ₃ labeled PEGylated and non-PEGylated cRGDFK peptide monomers. <i>Chemical Biology and Drug Design</i> , 2017, 89, 371-378.	3.2	6
49	Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 266-273.	1.0	2
50	A Freeze-Dried Kit for the Preparation of ¹⁸⁸ Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 139-144.	1.0	12
51	Formulation of clinical-scale ¹⁷⁷ Lu-PSMA-617: From laboratory to clinics. <i>Nuclear Medicine and Biology</i> , 2016, 43, 836.	0.6	0
52	¹⁷⁷ Lu-labeled carbon nanospheres: a new entry in the field of targeted radionanomedicine. <i>RSC Advances</i> , 2016, 6, 50761-50769.	3.6	9
53	Theranostic Treatment of Metastatic Bone Pain With ¹⁷⁷ Lu-DOTMP. <i>Clinical Nuclear Medicine</i> , 2016, 41, 966-967.	1.3	14
54	⁶⁸ Ga labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection. <i>Chemical Biology and Drug Design</i> , 2016, 87, 680-686.	3.2	22

#	ARTICLE	IF	CITATIONS
55	Neutral $^{99m}\text{Tc}(\text{CO})_3$ complexes of κ^2 -nitroimidazoles for the detection of tumor hypoxia. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 307, 69-77.	1.5	8
56	Preparation and bioevaluation of [^{99m}TcN] $_2$ -labeled tetrameric complex of E-c(RGDfk) $_2$ as a radiotracer for imaging $\alpha_5\beta_3$ integrins in tumors. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 309, 923.	1.5	7
57	Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole- κ^2 -dipicolylamine- $^{99m}\text{Tc}(\text{CO})_3$ complex for detecting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 46-50.	2.2	14
58	Convenient Preparation of [^{68}Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy. <i>Molecular Imaging and Biology</i> , 2016, 18, 420-427.	2.6	23
59	Synthesis and evaluation of a novel $^{99m}\text{TcN}(\text{PNP})$ -complex with metronidazole isocyanide ligand as a marker for tumor hypoxia. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 308, 363-369.	1.5	7
60	Clinical translation of ^{177}Lu -labeled PSMA-617: Initial experience in prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2016, 43, 296-302.	0.6	26
61	Synthesis and bioevaluation of a ^{177}Lu -labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 307, 1537-1544.	1.5	4
62	Evaluation of ^{177}Lu -EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy. <i>Current Radiopharmaceuticals</i> , 2015, 9, 64-70.	0.8	6
63	Pharmacokinetic, Dosimetry and Toxicity Study of ^{177}Lu -EDTMP in Patients: Phase 0/I study. <i>Current Radiopharmaceuticals</i> , 2015, 9, 71-84.	0.8	17
64	Theranostic Applications of Lutetium-177 in Radionuclide Therapy. <i>Current Radiopharmaceuticals</i> , 2015, 9, 94-101.	0.8	52
65	Utility of ^{99m}Tc -Hynic-TOC in ^{131}I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. <i>World Journal of Nuclear Medicine</i> , 2015, 14, 101.	0.5	5
66	Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of ^{177}Lu -Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience. <i>World Journal of Nuclear Medicine</i> , 2015, 14, 81-88.	0.5	19
67	Syntheses and biological evaluation of ^{99m}Tc -HYNIC-fatty acid complexes for myocardial imaging. <i>RSC Advances</i> , 2015, 5, 93374-93385.	3.6	5
68	A ^{99m}Tc -Labeled Misonidazole Analogue: Step Toward a ^{99m}Tc -Alternative to [^{18}F]Fluoromisonidazole for Detecting Tumor Hypoxia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 79-86.	1.0	10
69	Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale ^{177}Lu -DOTMP and ^{153}Sm -DOTMP at the hospital radiopharmacy. <i>Radiochimica Acta</i> , 2015, 103, 595-604.	1.2	5
70	Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications. <i>Chemical Reviews</i> , 2015, 115, 2934-2974.	47.7	203
71	Single vial freeze-dried TRODAT-1 kit: Preparation and demonstration of clinical efficacy of [^{99m}Tc]TRODAT-1 in Indian scenario. <i>Applied Radiation and Isotopes</i> , 2015, 96, 57-62.	1.5	1
72	Preparation of Therapeutic Dose of ^{177}Lu -DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ^{111}In -in-situ™ Preparation at Hospital Radiopharmacy. <i>Current Radiopharmaceuticals</i> , 2014, 7, 12-19.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Formulation, Preclinical Evaluation, and Preliminary Clinical Investigation of an In-House Freeze-Dried EDTMP Kit Suitable for the Preparation of ¹⁷⁷ Lu-EDTMP. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 412-421.	1.0	16
74	Radiosynthesis and Biological Evaluation of ⁶⁸ Ga-Labeled Colchicine Conjugates. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 251-256.	1.0	9
75	Improved Kit Formulation for Preparation of ^{99m} Tc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 387-394.	1.0	5
76	Formulation and radiochemical evaluation of a freeze-dried mixed peptide kit for the preparation of ⁶⁸ Ga-labeled peptides for PET imaging of somatostatin receptor positive neuroendocrine cancers. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 302, 1259-1264.	1.5	3
77	Synthesis and evaluation of a phenylbenzothiazole-based ^{99m} Tc(CO) ₃ -radiotracer for possible application in imaging of ¹²⁵ I-amyloid plaques in Alzheimer's disease. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 302, 1339-1344.	1.5	7
78	¹⁷⁷ Lu-EDTMP for Treatment of Bone Pain in Patients with Disseminated Skeletal Metastases. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 55-61.	0.8	39
79	Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of ¹⁷⁷ Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 299, 1389-1398.	1.5	14
80	A study on nitroimidazole- ^{99m} Tc(CO) ₃ complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. <i>Nuclear Medicine and Biology</i> , 2014, 41, 600-610.	0.6	26
81	Formulation of Patient Dose of ¹⁷⁷ Lu-DOTA-TATE in Hospital Radiopharmacy in India: Preparation Using In Situ Methodology Vis-a-Vis Freeze-Dried Kit. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 301-302.	1.0	2
82	Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2014, 2, 30-41.	0.1	1
83	A novel concept of radiosynthesis of a ^{99m} Tc-labeled dimeric RGD peptide as a potential radiotracer for tumor imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1808-1812.	2.2	8
84	Preparation and evaluation of a ^{99m} Tc- ⁶⁵ PNP complex of sanazole analogue for detecting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1394-1397.	2.2	7
85	Synthesis and Biological Evaluation of ⁹⁰ Y-Labeled Porphyrin-DOTA Conjugate: A Potential Molecule for Targeted Tumor Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 651-656.	1.0	16
86	Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 737-745.	1.0	15
87	Effect of lipophilicity on biological properties of ¹⁰⁹ Pd-porphyrin complexes: a preliminary investigation. <i>Journal of Porphyrins and Phthalocyanines</i> , 2012, 16, 64-71.	0.8	5
88	Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. <i>Radiochimica Acta</i> , 2012, 100, 115-126.	1.2	30
89	On the structural modification of 2-nitroimidazole- ^{99m} Tc(CO) ₃ complex, a hypoxia marker, for improving in vivo pharmacokinetics. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1236-1242.	0.6	26
90	Preparation of ^{99m} Tc(CO) ₃ -Carboxymethylthioethyl Iminodiacetic Acid and Evaluation as a Potential Renal Imaging Agent. <i>Current Radiopharmaceuticals</i> , 2012, 5, 65-70.	0.8	7

#	ARTICLE	IF	CITATIONS
91	¹⁰⁹ Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy. <i>Current Radiopharmaceuticals</i> , 2012, 5, 340-347.	0.8	10
92	Synthesis and Preliminary Bioevaluation of ^{99m} Tc(CO) ₃ -17 β -Triazolylandroster-4-Ene-3-One Derivative Prepared via Click Chemistry Route. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 539-545.	1.0	11
93	Reverse discordance™ between ⁶⁸ Ga-DOTA-NOC PET/CT and ¹⁷⁷ Lu-DOTA-TATE posttherapy scan. <i>Nuclear Medicine Communications</i> , 2011, 32, 654-658.	1.1	9
94	Radiosynthesis and in vitro evaluation of ^{99m} Tc(CO) ₃ -labeled folic acid derivative. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2011, 290, 89-93.	1.5	5
95	Synthesis, radiolabeling and evaluation of a new positively charged ^{99m} Tc-labeled fatty acid derivative for myocardial imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 150-156.	1.0	6
96	Stereoselective synthesis of an iodinated resveratrol analog: Preliminary bioevaluation studies of the radioiodinated species. <i>Applied Radiation and Isotopes</i> , 2011, 69, 996-1001.	1.5	6
97	Preparation of Patient Doses of ¹⁷⁷ Lu-DOTA-TATE Using Indigenously Produced ¹⁷⁷ Lu: The Indian Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 395-400.	1.0	19
98	Studies on Efficacy of a Novel ¹⁷⁷ Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model. <i>Current Radiopharmaceuticals</i> , 2011, 4, 150-160.	0.8	9
99	Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid- ^{99m} Tc(CO) ₃ complexes to target hypoxic tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 535-542.	1.0	30
100	Evaluation of new positively charged ¹¹ C and ¹² C carbon ^{99m} Tc-labeled fatty acid derivatives for myocardial imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 580-585.	1.0	6
101	N-Vanillylidene-L-histidine: Experimental Charge Density Analysis of a Double Zwitterionic Amino Acid Schiff-Base Compound. <i>Crystal Growth and Design</i> , 2010, 10, 1665-1676.	3.0	81
102	Biologic Evaluation of a Novel ¹⁸⁸ Re-Labeled Porphyrin in Mice Tumor Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 47-54.	1.0	25
103	Preparation of ¹⁷⁷ Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 539-543.	1.0	17
104	A novel ¹⁷⁷ Lu-labeled porphyrin for possible use in targeted tumor therapy. <i>Nuclear Medicine and Biology</i> , 2010, 37, 655-663.	0.6	32
105	Preparation and preliminary bioevaluation of ^{99m} Tc(CO) ₃ -11 β -progesterone derivative prepared via click chemistry route. <i>Nuclear Medicine and Biology</i> , 2010, 37, 997-1004.	0.6	13
106	¹⁶⁶ Ho-Labeled Hydroxyapatite Particles: A Possible Agent for Liver Cancer Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 7-14.	1.0	17
107	Preparation and bioevaluation of a ^{99m} Tc-labeled chlorambucil analog as a tumor targeting agent. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1644-1649.	1.5	25
108	¹⁷⁰ Tm-EDTMP: a potential cost-effective alternative to ⁸⁹ SrCl ₂ for bone pain palliation. <i>Nuclear Medicine and Biology</i> , 2009, 36, 561-568.	0.6	55

#	ARTICLE	IF	CITATIONS
109	Preparation and Evaluation of $^{99m}\text{Tc}(\text{CO})_3$ -Labeled Pentadecanoic Acid Derivative and Its Suspension in Lipiodol. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 503-507.	1.0	0
110	Preparation of ^{166}Ho -oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. <i>Nuclear Medicine Communications</i> , 2009, 30, 362-367.	1.1	16
111	Comparative studies of ^{177}Lu -EDTMP and ^{177}Lu -DOTMP as potential agents for palliative radiotherapy of bone metastasis. <i>Applied Radiation and Isotopes</i> , 2008, 66, 1196-1205.	1.5	68
112	Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7927-7931.	3.0	16
113	On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5233-5237.	2.2	36
114	Preparation and preliminary studies on ^{177}Lu -labeled hydroxyapatite particles for possible use in the therapy of liver cancer. <i>Nuclear Medicine and Biology</i> , 2008, 35, 589-597.	0.6	58
115	^{177}Lu -EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 202-213.	1.0	64
116	^{177}Lu -DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. <i>Radiochimica Acta</i> , 2008, 96, 55-61.	1.2	27
117	Preparation and <i>In-Vivo</i> Evaluation of $^{188}\text{Re}(\text{CO})_3$ -Colchicine Complex for Use as Tumor-Targeting Agent. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 741-748.	1.0	11
118	Synthesis of ^{99m}Tc -Nitrido Heterocomplex of Piperidine and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Its Affinity for Sigma Receptors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 34-42.	1.0	2
119	Preparation and biological studies of ^{125}I -DOTA-TATE. <i>Applied Radiation and Isotopes</i> , 2007, 65, 687-690.	1.5	4
120	On the preparation of a therapeutic dose of ^{177}Lu -labeled DOTA-TATE using indigenously produced ^{177}Lu in medium flux reactor. <i>Applied Radiation and Isotopes</i> , 2007, 65, 301-308.	1.5	35
121	Preparation and preliminary biological evaluation of ^{177}Lu -labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. <i>Nuclear Medicine Communications</i> , 2006, 27, 661-668.	1.1	45
122	Synthesis and evaluation of ether containing ^{99m}Tc -nitrido dithiocarbamate complexes as brain perfusion imaging agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 361-367.	1.5	15
123	Preparation and preliminary biological evaluation of a ^{166}Ho labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 462-469.	1.5	4
124	^{99m}Tc -labeling of colchicine using $[\text{}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ and $[\text{}^{99m}\text{TcN}]_2^+$ core for the preparation of potential tumor-targeting agents. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 793-799.	3.0	28
125	Evaluation of $^{99m}\text{Tc}(\text{CO})_3$ complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7666-7670.	3.0	38
126	A novel ^{99m}Tc -labeled testosterone derivative as a potential agent for targeting androgen receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5788-5792.	2.2	10

#	ARTICLE	IF	CITATIONS
127	Preparation and in vivo evaluation of ^{99m} TcN-tertiary butyl xanthate as a potential myocardial agent. Applied Radiation and Isotopes, 2006, 64, 663-667.	1.5	5
128	Preparation and bioevaluation of ^{99m} Tc-carbonyl complex of 5-hydroxy tryptamine derivative. Applied Radiation and Isotopes, 2006, 64, 888-892.	1.5	15
129	Preparation and preliminary biological evaluation of a ¹⁷⁷ Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy. Radiochimica Acta, 2006, 94, 375-380.	1.2	13
130	^{99m} TcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents. Nuclear Medicine Communications, 2005, 26, 1013-1019.	1.1	13
131	An estradiol-conjugate for radiolabelling with ¹⁷⁷ Lu: an attempt to prepare a radiotherapeutic agent. Bioorganic and Medicinal Chemistry, 2005, 13, 4315-4322.	3.0	15
132	A novel [^{99m} TcN] ₂ ⁺ complex of metronidazole xanthate as a potential agent for targeting hypoxia. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3398-3401.	2.2	55
133	Preparation and preliminary biological evaluation of a ¹⁷⁷ Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorganic and Medicinal Chemistry, 2004, 12, 6077-6084.	3.0	27
134	¹⁷⁵ Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Applied Radiation and Isotopes, 2004, 60, 635-642.	1.5	37
135	¹⁷⁷ Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nuclear Medicine and Biology, 2004, 31, 753-759.	0.6	27
136	Preparation and biological evaluation of ¹⁵³ Sm-DOTMP as a potential agent for bone pain palliation. Nuclear Medicine Communications, 2004, 25, 1169-1176.	1.1	20
137	Serum prolactin in seizure disorders. Indian Pediatrics, 2004, 41, 827-31.	0.4	8
138	Development of a Radioimmunoassay Procedure for Aflatoxin B1 Measurement. Journal of Agricultural and Food Chemistry, 2003, 51, 843-846.	5.2	37
139	^{99m} Tc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models. Nuclear Medicine and Biology, 2003, 30, 127-134.	0.6	24
140	¹⁷⁷ Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Applied Radiation and Isotopes, 2002, 57, 177-184.	1.5	61
141	Evolution of Tc- ^{99m} in diagnostic radiopharmaceuticals. Seminars in Nuclear Medicine, 2001, 31, 260-277.	4.6	212
142	Tc- ^{99m} and Re- ¹⁸⁶ complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. Nuclear Medicine and Biology, 2001, 28, 205-213.	0.6	26
143	Potential ¹⁶⁶ Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I: [¹⁶⁶ Ho] holmium labeled ethylene dicysteine. Nuclear Medicine and Biology, 2001, 28, 309-317.	0.6	18
144	¹⁸⁶ Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Nuclear Medicine and Biology, 2001, 28, 709-717.	0.6	11

#	ARTICLE	IF	CITATIONS
145	Syntheses and radiolabeling of cysteine-oximes and pharmacological behaviour of their ^{99m}Tc complexes. <i>Applied Radiation and Isotopes</i> , 2000, 52, 69-76.	1.5	7
146	Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker. <i>Applied Radiation and Isotopes</i> , 2000, 53, 987-991.	1.5	11
147	[$^{186}/^{188}\text{Re}$] rhenium-ethylene dicysteine (Re-Ec): preparation and evaluation for possible use in endovascular brachytherapy. <i>Nuclear Medicine and Biology</i> , 2000, 27, 189-197.	0.6	26
148	On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for ^{99m}Tc -meso- and d,l-HMPAO: a few additional observations. <i>Nuclear Medicine and Biology</i> , 1999, 26, 327-338.	0.6	7
149	Radiochemical studies of ^{99m}Tc complexes of modified cysteine ligands and bifunctional chelating agents. <i>Nuclear Medicine and Biology</i> , 1999, 26, 555-561.	0.6	18
150	An efficient and stereoselective synthesis of (2R,2 $\hat{\text{a}}^{\text{c}}\text{S}$)-1-O-(2 $\hat{\text{a}}^{\text{c}}$ -hydroxyhexadecyl)glycerol and its oxo analogs: Potential antitumour compounds from Shark Liver Oil. <i>Tetrahedron</i> , 1996, 52, 6437-6452.	1.9	16
151	Stereoselective total synthesis of (2R,2 $\hat{\text{a}}^{\text{c}}\text{S}$,3Z)-1-O-(2-methoxyhexadecenyl) glycerol and (2R,2 $\hat{\text{a}}^{\text{c}}\text{S}$)-1-(2 $\hat{\text{a}}^{\text{c}}$ -methoxyhexadecyl)glycerol-potential antitumour compounds from Shark liver oil. <i>Tetrahedron</i> , 1995, 51, 4723-4732.	1.9	6
152	Proxyl nitroxide of lithocholic acid: A potential spin probe for model membranes. <i>Bioorganic and Medicinal Chemistry</i> , 1993, 1, 341-347.	3.0	10
153	Synthesis of 2'-(3 $\hat{\text{I}}\pm$ -benzyloxy-24-norcholan-23-yl)-2',4',4'-trimethyl-4',5'-dihydrooxazoline-n-oxyl - a new potential spin probe for biomembranes. <i>Tetrahedron</i> , 1992, 48, 133-148.	1.9	14
154	Syntheses of potential spin probes for biomembranes - tempo and proxyl nitroxides of lithocholic acid. <i>Tetrahedron</i> , 1992, 48, 9939-9950.	1.9	16
155	Evaluation of Different Methods for the Detection of Anti- Thyroglobulin Autoantibody: Prevalence of Anti-Thyroglobulin Autoantibody and Anti-Microsomal Autoantibody in Thyroid Cancer Patients. <i>Indian Journal of Clinical Biochemistry</i> , 0, , 1.	1.9	0